Drugs / Peripheral blood mononuclear cells
Peripheral blood mononuclear cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02983708 | Aug 2011 → Sep 2014 | cerebral palsy, neurodegenerative disease | Hanyang University Seoul Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05421364 | Dec 2023 → Jan 2026 overdue | female infertility | Nadezhda Women's Health Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peripheral blood mononuclear cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05421364 ↗ |
| Known as | mPBMC | “Biological: Peripheral blood mononuclear cells (mPBMC)” NCT02983708 ↗ |
| Known as | PBMC | “Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)” NCT05421364 ↗ |
| Modality | Cell therapy | “using mPBMCs for cell therapy in children with CP” NCT02983708 ↗ |
| Route | Other | “infusion with autologous mobilized peripheral blood mononuclear cells (mPBMCs)” NCT02983708 ↗ |